225 related articles for article (PubMed ID: 16328065)
1. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression.
Muramaki M; Miyake H; Yamada Y; Hara I
Oncol Rep; 2006 Jan; 15(1):253-7. PubMed ID: 16328065
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
[TBL] [Abstract][Full Text] [Related]
3. Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression.
Miyake H; Hara I; Eto H
Anticancer Res; 2004; 24(4):2573-7. PubMed ID: 15330217
[TBL] [Abstract][Full Text] [Related]
4. Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer.
Xia HH; Yang Y; Chu KM; Gu Q; Zhang YY; He H; Wong WM; Leung SY; Yuen ST; Yuen MF; Chan AO; Wong BC
Cancer; 2009 Dec; 115(23):5441-9. PubMed ID: 19685530
[TBL] [Abstract][Full Text] [Related]
5. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression.
Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S
Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052
[TBL] [Abstract][Full Text] [Related]
6. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension.
Miyake H; Muramaki M; Furukawa J; Kurahashi T; Fujisawa M
Urology; 2010 Feb; 75(2):454-9. PubMed ID: 19854485
[TBL] [Abstract][Full Text] [Related]
7. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
Nam RK; Reeves JR; Toi A; Dulude H; Trachtenberg J; Emami M; Daigneault L; Panchal C; Sugar L; Jewett MA; Narod SA
J Urol; 2006 Apr; 175(4):1291-7. PubMed ID: 16515983
[TBL] [Abstract][Full Text] [Related]
8. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.
Meyer-Siegler KL; Iczkowski KA; Vera PL
BMC Cancer; 2005 Jul; 5():73. PubMed ID: 16000172
[TBL] [Abstract][Full Text] [Related]
9. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
11. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
12. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
[TBL] [Abstract][Full Text] [Related]
13. [Expression of macrophage migration inhibition factor (MIF) in serum of patients with prostate cancer and its clinical significance].
Tang WM; Gou X; Liu QX
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Jan; 27(1):97-8. PubMed ID: 21485220
[TBL] [Abstract][Full Text] [Related]
14. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
[TBL] [Abstract][Full Text] [Related]
16. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network.
Stephan C; Xu C; Brown DA; Breit SN; Michael A; Nakamura T; Diamandis EP; Meyer H; Cammann H; Jung K
Prostate; 2006 May; 66(6):651-9. PubMed ID: 16388506
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
19. Macrophage migration inhibitory factor in cancer.
Yasasever V; Camlica H; Duranyildiz D; Oguz H; Tas F; Dalay N
Cancer Invest; 2007 Dec; 25(8):715-9. PubMed ID: 18058468
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Eaton CL; Wells JM; Holen I; Croucher PI; Hamdy FC
Prostate; 2004 May; 59(3):304-10. PubMed ID: 15042606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]